Your browser doesn't support javascript.
loading
Conflicting or complementary role of computed tomography (CT) and positron emission tomography (PET)/CT in the assessment of thymic cancer and thymoma: our experience and literature review.
Scagliori, Elena; Evangelista, Laura; Panunzio, Annalori; Calabrese, Fiorella; Nannini, Nazarena; Polverosi, Roberta; Pomerri, Fabio.
Afiliación
  • Scagliori E; Oncologic Radiology Unit, Veneto Institute of Oncology IOV - IRCCS Padua, Italy.
  • Evangelista L; Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS Padua, Italy.
  • Panunzio A; Oncologic Radiology Unit, Veneto Institute of Oncology IOV - IRCCS Padua, Italy.
  • Calabrese F; Department of Cardiac, Thoracic and Vascular Science, University of Padua Padua, Italy.
  • Nannini N; Department of Cardiac, Thoracic and Vascular Science, University of Padua Padua, Italy.
  • Polverosi R; Department of Radiology, Hospital of San Donà di Piave Venice, Italy.
  • Pomerri F; Oncologic Radiology Unit, Veneto Institute of Oncology IOV - IRCCS Padua, Italy.
Thorac Cancer ; 6(4): 433-42, 2015 Jul.
Article en En | MEDLINE | ID: mdl-26273398
ABSTRACT

BACKGROUND:

To evaluate the role of computed tomography (CT) and positron emission tomography (PET)/CT in patients with thymic cancer and thymoma at initial staging.

METHODS:

We retrospectively reviewed CT and PET/CT scans of 26 patients with a thymic cancer (n = 9) or thymoma (n = 17). Chest CT findings documented were qualitative and quantitative. Both qualitative and semiquantitative data were recovered by PET/CT. The comparisons among histological entities, outcome, and qualitative data from CT and PET/CT were made by non-parametric analysis.

RESULTS:

PET/CT resulted positive in 15/17 patients with thymoma. CT was available in 5/9 (56%) patients with thymic cancer and in 3/17 with thymoma. All quantitative CT parameters were significantly higher in patients with thymic cancer than thymoma (maximum axial diameter 45 vs. 20 mm, maximum longitudinal diameter 69 vs. 21 mm and volume 77.91 vs. 4.52 mL; all P < 0.05). Conversely, only metabolic tumor volume (MTV) and total lesion glycolysis were significantly different in patients with thymic cancer than thymoma (126.53 vs. 6.03 cm3 and 246.05 vs. 20.32, respectively; both P < 0.05). After a median follow-up time of 17.45 months, four recurrences of disease occurred three in patients with thymic cancer and one with a type B2 thymoma. CT volume in patients with recurrent disease was 102.19 mL versus a median value of 62.5 mL in six disease-free patients. MTV was higher in the recurrent than disease-free patient subset (143.3 vs. 81.13 cm(3)), although not statistically significant (P = 0.075).

CONCLUSION:

Our preliminary results demonstrated that both morphological and metabolic volume could be useful from a diagnostic and prognostic point of view in thymic cancer and thymoma patients. A large multi-center clinical trial experience for confirming the findings of this study seems mandatory.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Idioma: En Revista: Thorac Cancer Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: SG / SINGAPORE / SINGAPUR / SINGAPURA

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Idioma: En Revista: Thorac Cancer Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: SG / SINGAPORE / SINGAPUR / SINGAPURA